Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Tyroserleutide TFA, a tripeptide derived from porcine spleen degradation products [1], exhibits antitumor activity in vitro and in vivo [2]. |
In vitro | Tyroserleutide (YSL) demonstrates immunomodulatory properties by enhancing concanavalin (ConA)-induced proliferation of mouse spleen lymphocytes, phagocytosis by mouse peritoneal macrophages, and natural killer (NK) cell activity [1]. Furthermore, as an immunotherapeutic tripeptide, YSL promotes apoptosis in hepatocarcinoma cells (H22) by downregulating Bcl-2 and cyclin D1 expression, positioning it as an effective agent for liver tumor cell apoptosis [2]. It also inhibits tumor growth and migration without causing significant toxicity in major organs [2]. |
In vivo | Administered via intraperitoneal injection at doses ranging from 10 to 80 μg/kg once daily until mortality, Tyroserleutide exhibits pronounced anti-tumor effects, notably extending the lifespan of mice implanted with H22 murine hepatocarcinoma cells [1]. |
Cas No. |
Storage | keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.